Log in
Show password
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

IQVIA : and NRx Pharmaceuticals Collaborate on Potential Medical Support for Novel COVID-19 Treatment

09/13/2021 | 04:16pm EDT

IQVIA™ (NYSE:IQV), a leading global provider of advanced analytics, technology solutions and clinical research services to the life sciences industry, today announced a transformative collaboration with NRx Pharmaceuticals (NRx) (Nasdaq: NRXP). NRx is a company dedicated to creating innovative, life-saving treatments and bringing hope to those facing life-altering conditions with no approved disease-modifying therapies or cures. IQVIA is excited to collaborate with NRx as its designated partner, to provide pharmacovigilance services and medical information in preparation for potential regulatory actions.

"As the world suffers yet another surge of COVID-19, thousands of patients require intensive care and too many succumb to this virus. New medicines with new mechanisms of action are urgently needed," said Robert Besthof, chief commercial officer and head of Operations of NRx. "As a small biopharma company preparing to launch a lifesaving medicine across multiple countries, we deeply appreciate the global reach that IQVIA is able to offer in support of patients, families, and those who care for them.”

This collaboration will allow NRx to access IQVIA’s domain experience with COVID-19, our unparalleled data assets, and analytics to support potential emergency use authorization (EUA) of ZYESAMI. IQVIA will work closely with NRx to support key activities required for EUA activation, including the pharmacovigilance and medical information programs.

“We are honored by the opportunity to join with NRx on the EUA activation and compliance for ZYESAMI in treating some of the sickest patients suffering from COVID-19,” said Susan Kitlas, vice president, Precommercial Business Unit, IQVIA. “IQVIA’s experience and expertise within the COVID-19 market will be a valuable component in helping make this treatment more widely available.”

About NRx
NRx Pharmaceuticals (NASDAQ-GS:NRXP) draws upon more than 300 combined years of scientific and drug-development experience to bring improved health to patients. Its investigational product, ZYESAMI™ (aviptadil) for patients with COVID-19, has been granted Fast Track designation by the US Food and Drug Administration and is currently undergoing phase 3 trials funded by the US National Institutes of Health, the Biomedical Advanced Research and Development Authority part of the US Department of Health and Human Services, and the Medical Countermeasures program, part of the US Department of Defense.

IQVIA (NYSE:IQV) is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources and extensive domain expertise. IQVIA Connected Intelligence™ delivers powerful insights with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 74,000 employees, IQVIA conducts operations in more than 100 countries.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.

© Business Wire 2021
All news about IQVIA HOLDINGS INC.
10/22IQVIA : Morgan Stanley Adjusts Price Target on IQVIA Holdings to $290 from $280, Keeps Ove..
10/22IQVIA : Management's Discussion and Analysis of Financial Condition and Results of Operati..
10/21IQVIA : Q3 2021 IQVIA Earnings Conference Call Presentation
10/21Health Care Stocks Steady Pre-Bell Thursday
10/21IQVIA : Q3 Adjusted Earnings, Revenue Rise; Issues Q4 Outlook; Raises Full-Year 2021 Guida..
10/21IQVIA : Q3 Earnings Snapshot
10/21IQVIA : Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance - Form 8-K
10/21IQVIA HOLDINGS INC. : Results of Operations and Financial Condition (form 8-K)
10/21IQVIA : Reports Third-Quarter 2021 Results and Raises Full-Year 2021 Guidance
10/21GUIDANCE : (IQV) IQVIA HOLDINGS Expects Fiscal Year 2021 Revenue Range $13.77B - $13.85B
More news
Analyst Recommendations on IQVIA HOLDINGS INC.
More recommendations
Financials (USD)
Sales 2021 13 827 M - -
Net income 2021 907 M - -
Net Debt 2021 10 665 M - -
P/E ratio 2021 55,1x
Yield 2021 -
Capitalization 49 076 M 49 076 M -
EV / Sales 2021 4,32x
EV / Sales 2022 3,92x
Nbr of Employees 77 000
Free-Float 74,2%
Duration : Period :
IQVIA Holdings Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IQVIA HOLDINGS INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 18
Last Close Price 256,89 $
Average target price 285,94 $
Spread / Average Target 11,3%
EPS Revisions
Managers and Directors
Ari Bousbib Chairman, President & Chief Executive Officer
Ronald Earl Bruehlman Chief Financial Officer & Executive Vice President
Karl Guenault Chief Information Officer & Senior Vice President
W. Richard Staub President-Research & Development Solutions
Kevin C. Knightly President-Technology & Commercial Solutions
Sector and Competitors
1st jan.Capi. (M$)
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455